About the Continued Evaluation of MK-1084 for NSCLC and More

Carlos Rojas, MD, medical oncology, Centro de Investigacion Clinica, Bradford Hill, discusses the next steps for evaluating MK-1084 in a phase 1 trial (NCT05067283) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) and advanced solid tumors.

MK-1084 is a selective KRAS G12C inhibitor. In the open-label, global, dose-escalation, phase 1 study, investigators are assessing the agent alone in patients with advanced solid tumors, as well as in combination with pembrolizumab (Keytruda) for the first-line treatment of metastatic NSCLC.

Transcription:

0:09 | We will open new arms for colorectal and for non-small cell lung cancer in [the] frontline in both, and in colorectal cancer, also in later lines in combination with cetuximab. And also, we will try another formulation of the drug looking for a best response in patients with any tumor that harbored this mutation.

0:38 | Another thing that is important, because 1 of the questions is well, we had sotorasib and adagrasib, [but] there will be another pharma developing drugs for this target. But I think that it is important to have more competition and more drugs. At least in countries like mine, I am not from a highly developed country, and when [we] have more options, the access to the drugs will be easier. So that is also an important thing because when [we] have a high number of drugs for the same target, and all the drugs are good drugs, I think that will [make it] easier for countries like mine to have access to these new treatments.

REFERENCE:

Rojas C. Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. Presented at: ESMO 2023; September 29 - October 3, 2023; Madrid, Spain. Abstract 663P.